Follow The Filings

MLTX Moonlake Immunotherapeutics

Health Care, filed as MOONLAKE IMMUNOTHERAPEUTICS (CLASS A ORD), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 exit

In 2026 Q2 David Witzke sold out of Moonlake Immunotherapeutics.

Who owns MLTX

Sorted by value, long equity only, as of 2026 Q2.

History
David Witzke, Avidity Partners Management exited 2026 Q2 Last 2026 Q1 0.19% Exit −0.19% 50,000 $819K History

0 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by MLTX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All MLTX insider trades
  • None no insider bought on the open market
  • $65.7M sold by 2 insiders outside a trading plan
  • $9.7M sold by 3 insiders under 10b5-1 plans
  1. Kristian Reich Chief Scientific Officer
    Planned sale
    $22K 1,100 shares at $20.00 <0.1% of stake
    Traded Jul 27 Filed Jul 29
    ↗
  2. Kristian Reich Chief Scientific Officer
    Planned sale
    $1M 52,448 shares at $20.02 1.9% of stake
    Traded Jul 21–22 Filed Jul 23
    ↗
  3. Kristian Reich Chief Scientific Officer
    Planned sale
    $878K 43,700 shares at $20.09 1.6% of stake
    Traded Jul 20 Filed Jul 21
    ↗
  4. Kristian Reich Chief Scientific Officer
    Planned sale
    $322K 16,105 shares at $20.01 0.6% of stake
    Traded Jul 15 Filed Jul 20
    ↗
  5. Da Silva Jorge Santos CEO
    Planned sale
    $2M 102,225 shares at $20.02 3.6% of stake
    Traded Jul 9–10 Filed Jul 13
    ↗
  6. Da Silva Jorge Santos CEO
    Planned sale
    $957K 47,775 shares at $20.03 1.6% of stake
    Traded Jul 1 Filed Jul 2
    ↗
  7. Matthias Bodenstedt CFO
    Planned sale
    $862K 39,120 shares at $22.04 3.4% of stake
    Traded Jun 22 Filed Jun 23
    ↗
  8. Matthias Bodenstedt CFO
    Planned sale
    $352K 17,876 shares at $19.67 1.5% of stake
    Traded Jun 17–18 Filed Jun 18
    ↗
  9. Kristian Reich Chief Scientific Officer
    Planned sale
    $2.9M 150,000 shares at $19.01 5% of stake
    Traded Jun 15–17 Filed Jun 17
    ↗
  10. Matthias Bodenstedt CFO
    Planned sale
    $273K 13,653 shares at $20.02 1.2% of stake
    Traded May 11 Filed May 13
    ↗
  11. Matthias Bodenstedt CFO
    Planned sale
    $47K 2,426 shares at $19.56 0.2% of stake
    Traded Apr 14 Filed Apr 16
    ↗
  12. Da Silva Jorge Santos CEO
    Sale
    $2.8M 150,000 shares at $18.35 4.9% of stake
    Traded Apr 10–13 Filed Apr 14
    ↗
  13. Bvf Partners L P Director, +9 joint filers
    Sale
    $63M 3,750,000 shares at $16.79 78% of stake
    Traded Mar 31 Filed Apr 2
    ↗
  14. Matthias Bodenstedt CFO
    Buy
    $99K 10,870 shares at $9.09 +1.8% to stake
    Traded Oct 8, 2025 Filed Oct 9, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 6 sales to cover taxes, 3 conversions, 3 sales back to the company, and 1 stock grant.

SEC filings

Recent issuer filings from EDGAR, 21 shown.

Filed Form Detail Links
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01,9.01 Filing Doc
424B5 PROSPECTUS SUPPLEMENT Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
424B5 PRELIMINARY PROSPECTUS SUPPLEMENT Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
8-K 1.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13D/A — Filing Doc
10-K Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$36.01M -$118.94M -$227.32M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $514.17M $474.29M $421.69M
Total non-current assets $12.37M $3.64M $2.74M
Total assets $526.54M $477.93M $424.43M
Total current liabilities $9.97M $22.46M $45.48M
Total non-current liabilities $3.08M $2.08M $74.47M
Total equity $495.68M $446.83M $304.48M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$42.78M -$116.59M -$196.01M
Cash from investing -$25.18M -$205.6M $202.99M
Cash from financing $479.7M $51.31M $146M
Net change in cash $411.66M -$270.74M $154.09M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.